Skip to main content

Table 2 Summary of published screening studies grouped by screening design

From: Recommendations for patient screening in ultra-rare inherited metabolic diseases: what have we learned from Niemann-Pick disease type C?

Cohort (reference)

Study population

N

Region/country

Primary screening method(s)

Prospective patient screening studies

 Genetic screening

  Bauer et al. 2013 [31]

Adults with neurological/psych. Symptoms

250

EU and US

NPC1/NPC2 sequencinga, gene dosage analysis

  Schicks et al. 2013 [32]

Adults with ataxia, EOCD and suspected recessive disease

24

Germany

NPC1/NPC2 sequencinga

  Zech et al. 2013 [36]

Adults with PD, FTD or PSP

790

Germany

HRM followed by NPC1/NPC2 sequencinga

  Nanetti et al. 2017 [33]

Adults with suspected HD

18

Italy

NPC1/NPC2 sequencinga

  Topcu et al. 2017 [34]

Family members of NPC1/NPC2 probands

510

Turkey

NPC1/NPC2 sequencinga

  Cupidi et al. 2017 [35]

Adults with early-onset ‘dementia-plus’

50

Italy

NPC1/NPC2 sequencinga, gene dosage analysis

  Synofzik et al. 2015 [27]

Adolescents/adults with unexplained EOA

96

Germany

NPC1/NPC2 (NGS gene panelb)

  Marelli et al. 2016 [40]

Adolescents/adults with probable EOA

33

France

NPC1/NPC2 (NGS gene panel)

  Pyle et al. 2015 [41]

Adult patients with inherited and sporadic ataxias

35

UK

NPC1/NPC2 sequencing (WES)

  McKay et al. 2014 [42]

Infants with jaundice/cholestasis

228

UK

NPC1/NPC2 sequencing (WES)

  Herbst et al. 2015 [43]

Infants with jaundice/cholestasis

6

Germany

NPC1/NPC2 sequencing (NGS gene panel)

  Mavridou et al. 2014 [70]

Family members of NP-C patients

153

Greece

NPC1/NPC2 sequencinga, RFLP analysis

  Wassif et al. 2016 [14]

Subjects from 4 WES sequencing projects

17,754c

International

Historical WES + WES from public databases

 Blood biomarker screening

  Reunert et al. 2016 [44]

Patients with suspected NP-C

1800

Germany

Oxysterol level (C-triol)

  Ribas et al. 2016 [45]

Patients with suspected NP-C

122

Brazil

Oxysterol level (C-triol), ChT

  Zhang et al. 2014 [46]

Children/adults with cholestasis, HSL or psychomotor regression/retardation

302

China

Oxysterol level (7-KC)

  De Castro et al. 2017 [47]

Patients with suspected NP-C

236

Spain

ChT, CCL18/PARC, NPC1/NPC2 sequencinga

  Sheth et al. 2014 [48]

Children with possible LSDs

1110

India, Sri Lanka, Afghanistan

Urine GAGs, plasma ChT, enzyme activity

Studies based on archived (biobank) samples

 Cebolla et al. 2015 [50]

Patients with NP-C

97

Spain

Oxysterol level (7-KC)

Studies based on patient file and clinical chart review

 Yerushalmi et al. 2002 [51]

Neonates with jaundice/cholestasis

40

US

Medical chart review

 Hegarty et al. 2015 [52]

Children with acute liver failure

127

UK

Clinical, laboratory, and outcome analysis

 Verity et al. 2010 [53]

Children with early cognitive impairment

2636

UK

Clinical case surveillance

 Winstone et al. 2017 [54]

Children with intellectual and neurological deterioration

3979

UK

Clinical case surveillance

 Corry 2014 [55]

Ethnic subjects with suspected autosomal recessive conditions

13,000

UK

Clinical case surveillance

Studies based on newborn screening

 Pinto et al. 2004 [60]

Antenatal patients with suspected LSDs

353

Portugal

NPC1/NPC2 sequencinga

 Polo et al. 2016 [61]

Neonates with cholestasis

7

Italy

Oxysterols (7-KC, C-triol)

  1. aSanger sequencing; bMini-exome sequencing of ̴5,000 genes; cWES of 17,754 chromosomes. ChT chitotriosidase, CNV copy-number variation, EOA early-onset ataxia, EOCD early-onset cognitive decline, FTD frontotemporal dementia, GAG glycosaminoglycans, HRM high resolution melting, HSL hepatosplenomegaly, LSD lysosomal storage disease, NGS next-generation sequencing, PD Parkinson’s disease, PSP progressive supranuclear gaze palsy, Psych. psychiatric, RFLP restriction fragment length polymorphism, WES whole-exome sequencing